- Home
- FBIO vs DXR Comparison
FBIO vs DXR Comparison
Compare FBIO & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- DXR
- Stock Information
- Founded
- FBIO 2006
- DXR 1970
- Country
- FBIO United States
- DXR United States
- Employees
- FBIO N/A
- DXR N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- DXR Medical/Dental Instruments
- Sector
- FBIO Health Care
- DXR Health Care
- Exchange
- FBIO Nasdaq
- DXR Nasdaq
- Market Cap
- FBIO 39.4M
- DXR 42.6M
- IPO Year
- FBIO N/A
- DXR N/A
- Fundamental
- Price
- FBIO $1.43
- DXR $9.01
- Analyst Decision
- FBIO Strong Buy
- DXR Strong Buy
- Analyst Count
- FBIO 4
- DXR 1
- Target Price
- FBIO $16.33
- DXR $24.75
- AVG Volume (30 Days)
- FBIO 605.0K
- DXR 7.6K
- Earning Date
- FBIO 11-14-2024
- DXR 01-01-0001
- Dividend Yield
- FBIO N/A
- DXR N/A
- EPS Growth
- FBIO N/A
- DXR N/A
- EPS
- FBIO N/A
- DXR 0.35
- Revenue
- FBIO $81,501,000.00
- DXR $154,205.00
- Revenue This Year
- FBIO N/A
- DXR N/A
- Revenue Next Year
- FBIO $81.63
- DXR N/A
- P/E Ratio
- FBIO N/A
- DXR $25.85
- Revenue Growth
- FBIO 31.51
- DXR N/A
- 52 Week Low
- FBIO $1.36
- DXR $7.11
- 52 Week High
- FBIO $4.43
- DXR $10.04
- Technical
- Relative Strength Index (RSI)
- FBIO 31.19
- DXR 49.80
- Support Level
- FBIO $1.66
- DXR $8.53
- Resistance Level
- FBIO $1.79
- DXR $9.10
- Average True Range (ATR)
- FBIO 0.13
- DXR 0.47
- MACD
- FBIO -0.04
- DXR -0.01
- Stochastic Oscillator
- FBIO 2.90
- DXR 35.71
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.